Bristol-Myers Sues Genentech Over ‘Cabilly’ Patents

Bristol-Myers Squibb Co. (BMY) sued Roche Holding AG (ROG)’s Genentech unit seeking a ruling it doesn’t infringe patents used to make treatments for cancer and autoimmune diseases.

The patents, known as “Cabilly” after one of the inventors, are invalid and not infringed by colon cancer and melanoma treatments New York-based Bristol-Myers sells in the U.S., the company’s attorneys claimed in a complaint filed May 3 in federal court in Oakland, California.

“Bristol-Myers Squibb brings this action to lift the cloud created by the imminent threat of defendant’s enforcement of the Cabilly patents against the plaintiffs,” according to the complaint. “Without declaratory relief the threat of enforcement of the Cabilly patents poses a substantial risk to the plaintiffs as well as to patients, nurses and doctors now using Erbitux and Yervoy.”

Erbitux, made by Indianapolis-based Eli Lilly & Co. (LLY)’s ImClone unit, is approved in the U.S. to treat colon cancer and head and neck tumors and sold by Bristol-Myers in the U.S. Yervoy, a melanoma treatment, is manufactured and sold by Bristol-Myers in the U.S.

Genentech’s media office didn’t immediately return a phone message seeking comment on the lawsuit.

Eli Lilly filed a similar lawsuit over the Cabilly patents in March.

The case is Bristol-Myers Squibb v. Genentech, 13-cv-02045, U.S. District Court, Northern District of California (Oakland_

To contact the reporter on this story: Karen Gullo in San Francisco at

To contact the editor responsible for this story: Michael Hytha at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.